 |
 |
|||||||
Showcase your company to over 8000 key decision makers worldwide within the pharmaceutical and biotech sectors.Pharmaceutical and biotechnology executives refer to the Drug Delivery Report (DDR) throughout the year as the main method of independently assessing drug delivery partners.
If you want to complete a deal in 2006, then advertising in the Drug Delivery Report Autumn/Winter 2006 and on drugdeliveryreport.com is a must. Contact Wayne Chivell on +44 (0) 1865 784 177 or e-mail enquiries@pharmaventures.com to find out how you can promote your company. Copy Deadline: 22nd September 2006 |
||||||||
 |
 |
|||||||
 |
Market News and TrendsDuring July 2006, PharmaDeals® Agreements recorded a total of only 8 deals relating to drug delivery, the lowest monthly total so far for 2006. Start-up companies featured in 7 deals; three of which were with established companies, and one each with a fellow start-up company, an academic body, a governmental organisation and a global company. Three of the 8 deals involved licensing agreements; three were co-development or collaborative R&D transactions; the remaining two were marketing and contract agreements. A range of interest areas were represented including immunological and sensory, genitourinary (2 deals), medical devices (2 deals), anti-infective and cardiovascular. Two deals involved start-up company Antares and another deal furthered the development of an innovative and improved anthrax vaccine. Read more... |
||
|
|
||
Featured ArticleA Renaissance in Peptide Therapeutics is UnderwayIt has long been recognised that peptide and protein drugs are among the most useful and effective therapeutics yet discovered. However, the practical use of most peptide drugs has been confined to treatment of diseases having severe or life threatening consequences as a direct result of the requirement for administration by injection. In this article, Edward T. Maggio, CEO of Aegis Therapeutics, discusses the current rebirth in interest in peptide drugs. This has been brought about by improvements across the board in transmucosal drug delivery, comprising new routes of administration, new delivery devices and breakthroughs in formulation technology. Read more... |
 |
||
|
|
||
 |
Company Profilesfertin Pharma, Innovata, Magenta Oral Dose Design, Phares Drug Delivery |
||
|
|
||
Drug Delivery OpportunitiesView all our Drug Delivery Opportunities or alternatively request a password to submit your opportunity online.Featured Opportunity 7 Day Discreet Transdermal Pain Patch Administrative Route - Transdermal Indication - Moderate-to-severe chronic pain Licence code - LO-0805-05 |
 |
||
|
|
||
 |
Ensure you receive your copy of the Drug Delivery Report Autumn / Winter 2006For deal makers actively assessing drug delivery technology receiving your complimentary copy is a must. The DDR blends high-quality articles covering the latest drug developments in conjunction with concise profiles of companies active in specific technology areas.Apply to receive the next edition of the DDR Find out more about promoting your company |
||
Comprising two specialist areas - PharmaVentures Consulting and PharmaVentures Intelligence - we work with clients to drive greater value from their deals.
If you do not wish to receive DDR E-News in future, please e-mail ddr@pharmamail.biz with the words UNSUBSCRIBE as the subject.
If you do not wish to receive other e-mail communications from PharmaVentures or selected third parties, please e-mail ddr@pharmamail.biz with REMOVE as the subject.
For more details contact
Kate Atherton, Publishing Editor, PharmaVentures Ltd, Magdalen Centre, Oxford Science Park, Oxford OX4 4GA, UK. Tel: +44 (0) 1865 784 177 Fax: +44 (0) 1865 784 178 E-mail ddr@pharmamail.biz